NAME: Scott M. Hammer, MD ACADEMIC TITLE: Chief, Division of Infectious Diseases Harold C. Neu Professor of Medicine Professor of Epidemiology

EDUCATION:
Columbia College, BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972

SPECIALTY: HIV pathogenesis, therapy, and vaccine development

RESEARCH SUMMARY:

Dr. Hammer is the Harold C. Neu Professor of Medicine, Professor of Epidemiology and Chief of the Division of Infectious Diseases at the NewYork-Presbyterian/Columbia University Medical Center (NYP-CUMC).  Dr. Hammer’s major investigative interest is the treatment and prevention of HIV disease.  He is an investigator in the National Institutes of Health sponsored AIDS Clinical Trials Group (ACTG), a multicenter organization which performs clinical trials designed to improve the understanding and treatment of HIV infection and its complications.  As an ACTG investigator, Dr. Hammer chaired the two largest national trials of antiretroviral therapy carried out by that group in the 1990’s, studies which contributed to the current standard of care of HIV infection.  In addition to his interest in the treatment of persons with established HIV infection, Dr. Hammer is an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine.  He is the current protocol chair of HVTN 505, an advanced phase II study of the preventive HIV vaccine regimen developed by NIAID’s Vaccine Research Center.  He is a former Chair of the AIDS Vaccine Research Working Group of the Division of AIDS, NIAID, and the Antiviral Products Advisory Committee of the Food and Drug Administration and currently serves on the Editorial Board of the New England Journal of Medicine.  Dr. Hammer is a former Chair of the International AIDS Society-USA’s Antiretroviral Guidelines Panel and former Vice Chair of the World Health Organization’s Strategic and Technical Advisory Committee for HIV/AIDS.  He chaired the Guidelines Development Group of the WHO’s Antiretroviral Guidelines for Resource Limited Settings in 2002, 2003 and 2006 and co-chaired the Steering Committee of the WHO’s Global HIV Drug Resistance Surveillance Program.  In his role as Chief of the Division of Infectious Diseases at CUMC, he is dedicated to fellow and faculty growth and to the development of state-of-the-art infection surveillance at the institutional and regional levels to improve and protect the public health.

SELECTED PUBLICATIONS:

Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (for the ACTG 175 study team). A trial of nucleoside monotherapy vs. combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter: NIAID-sponsored AIDS clinical trials group study 175. N Engl J Med. 1996;335:1081-1096.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (for the AIDS clinical trials group 320 study team). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.

Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: Cellular and humoral immune responses. Ann Intern Med. 2001;134:761-776.

Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978-996.

Hammer SM. Increasing choices for HIV therapy. N Engl J Med. 2002;346:2022-2023.

Hammer S, Gibb D, Havlir D, Mofenson L, VAn Beek I, Vella S, Vareldzis B, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. World Health Organization, April 2002, available at www.who.int.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, and Mellors JW (for the AIDS clinical trials group 398 study team). Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc. 2002;288:169-180.

Hammer SM, Bassett R, Squires KE, Fischl M, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, and DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8:507-518.

Hammer SM, Mofenson L, Havlir D, Vitorio M, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 version. World Health Organization, December 2003, available at www.who.int.

Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.

Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2006;14:36-62.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006;296:827-43.

Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR; A5118 Team. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11:619-23.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14:827-43.

Hammer S, Riley A, Calmy A, Harries A, Duncombe C, Havlir D, Katabira E, Scano F, Malkin JE, Lange J, Mukerjee J, Currier J, Mofenson L, Harrington M, Schechter M, Kumarasamy N, Sow PS, Munderi P, Ojoo S, Cahn P, Phanuphak P, Eholie S, El Sadr W, Rodriguez W: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. World Health Organization, August 2006, available at www.who.int.

Taylor BS, Sobieszczyk ME, McCutchan FE and Hammer SM:  The challenge of HIV-1 subtype diversity.  NEJM 2008;358:1590-1602.

Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM and Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-285

Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG and Volberding PA:  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA Panel.  JAMA 2008; 300:555-570.

Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S and Squires K: Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008;9:11-25

Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. HIV vaccine research: the way forward. Science. 2008 Jul 25;321(5888):530-2.

 

Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L. Persistent minority K103Nmutations among women exposed to single-dose nevirapine and virologic response tononnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15;48(4):462-72.

 

Castor D, Vlahov D, Hoover DR, Berkman A, Wu YF, Zeller B, Brechtl J, Hammer SM. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. J Med Virol. 2009

Aug;81(8):1323-35.

 

Montaner JS, Richman DD, Hammer SM; International AIDS Society-USA Antiretroviral Guidelines Panel. Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis. 2009 Oct 15;49(8):1283-4.

Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 Jul 21;304(3):321-33.

 

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine

Trials Network 050 Study Team. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. 2010 Nov 23.

 

Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis. 2011 Apr 1;203(7):969-75.

 

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One. 2011 Apr 13;6(4):e18526.

Hammer SM. Antiretroviral treatment as prevention. N Engl J Med. 2011 Aug 11;365(6):561-2.

 

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012

recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25;308(4):387-402.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: (212) 305-7185
Fax: (212) 305-7290
E-mail: smh48@columbia.edu

 

NAME: Karen Brudney, MD

ACADEMIC TITLE:
Assistant Clinical Professor of Medicine

EDUCATION:
Yale University, BA, 1973
Columbia University College of Physicians and Surgeons, MD, 1980

SPECIALTY: Tuberculosis, HIV therapy, HIV primary care, patient adherence and access to care

RESEARCH SUMMARY:
Dr Brudney is the director of the Infectious Disease/AIDS Clinic and the director of TB service at NewYork–Presbyterian Hospital. She is also the program director for the Treatment Adherence Demonstration Project. In order to improve antiretroviral adherence in difficult populations, an interdisciplinary program called Jumpstart was initiated in 1998 in the Infectious Disease/AIDS Clinic at NewYork–Presbyterian Hospital. Results from this successful program are currently being analyzed. Dr Brudney is also the recipient of a Fogarty Award for AIDS International Training and Research to deliver HIV treatment and study the epidemiology of sexually transmitted diseases in Santo Domingo, Dominican Republic.

SELECTED PUBLICATIONS:
Brudney K, Dobkin JF. Resurgent tuberculosis in New York City: HIV homelessness and the decline of TB control programs. Am Rev Respir Dis. 1991;144:745-749.

Brudney K, Dobkin JF. A tale of two cities: TB control in Nicaragua and New York. Sem Resp Inf. 1991;6:261-272.

Brudney K. Homelessness and tuberculosis: A study in failure. J Law Med Eth. 1993;23:360-367.

Frieden TR et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: Epidemiology and clinical outcomes. JAMA. 1996;276:1229-1235.

Sackoff J et al. Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in NYC. AIDS. 1998;12:2017-2023.

Ellerbock TV et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.

Wilkin TJ, Palmer S, Brudney KF, Chiasson MA, Wright TC. Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to anti-retroviral therapy. J Infect Dis. 2004;190:1685-1691.

Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV-infected postmenopausal women. Osteoporos Int. 2005;16:1345-1352.

Furuya EY, Paez A, Srinivasan A, Cooksey R, Augunbraun M, Baron M, Brudney K, Della-Latta P, Concepcion E, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV. “Outbreak of Mycobacterium abscessus wound infections among ‘Lipotourists’ from the United States who underwent abdominoplasty in the Dominican Republic.” Clinical Infectious Diseases 46:1181-8; 2008.

OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-7068
Fax: 212-305-7692
E-mail: Kfb2@columbia.edu

NAME: Mary Ann Chiasson, MS, MPH, DrPH ACADEMIC TITLE: Associate Professor of Clinical Epidemiology (in Medicine)

EDUCATION:
Bennington College, BA, 1972
New York University, MS, 1978
Columbia University Mailman School of Public Health, MPH, 1985
Columbia University Mailman School of Public Health, DrPH, 1988

SPECIALTY: Epidemiology of HIV, HPV, and other STIs; reproductive health

RESEARCH SUMMARY:

Dr. Mary Ann Chiasson is an epidemiologist with a part-time faculty appointment in the Division of Infectious Diseases. Her primary appointment is in the Epidemiology Division at Columbia's Mailman School of Public Health where she has co-directed  the Epidemiology of HIV/AIDS course since 1989. Dr Chiasson has been the vice president for research and evaluation at Public Health Solutions since 1999. Before joining Public Health Solutions, she served for nine years as an assistant commissioner of health at the New York City Department of Health with scientific and administrative responsibility for AIDS surveillance, HIV/AIDS research and vital statistics, and epidemiology. Dr Chiasson's research interests include the epidemiology of HIV (particularly risk factors for sexual transmission and gynecologic manifestations of HIV), women's reproductive health, and infant mortality. Her current research focuses on the relationship between the Internet and high risk sexual behavior among men who have sex with men. The online HIV prevention videos produced by the research collaboration she leads can be viewed at http://www.hivbigdeal.org/.

SELECTED PUBLICATIONS:
Sun X-W, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1349.

Chiasson MA, Berenson L, Li W, Schwartz S, Singh T, Forlenza S, Mojica BA Hamburg MA. Declining HIV/AIDS mortality in New York City. JAIDS.1999;21:59-64.

Ellerbrock TV, Chiasson MA, Bush TJ, Sun X-W, Sawo D, Brudney K, Wright TC. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.

Chiasson MA, Parsons JT, Tesoriero JM, Carballo-Dieguez A, Hirshfield S, Remien RH. HIV behavioral research online. J Urban Health 2006; 83:73-85.

Aidala AA, Lee G, Garbers S, Chiasson MA. Sexual behavior and sexual risk in a prospective cohort of HIV-positive men and women in New York City, 1994-2002: Implications for prevention. AIDS Educ Prev 2006; 18:12-32.

Chiasson MA, Hirshfield S, Remien RH, Humberstone M, Wong T, Wolitski RJ. A comparison of online and offline sexual risk in men who have sex with men: An event-based online survey 2006. JAIDS 2007;44:235-243.

Chiasson MA, Shuchat Shaw F, Humberstone M, Hirshfield S, Hartel D. Increased HIV disclosure three months after an online video intervention for men who have sex with men (MSM). AIDS Care 2009; 21:1081-1089.

MA Chiasson, S Hirshfield, C Rietmeijer. HIV Prevention and Care inthe Digital Age. J Acquir Immune Defic Syndr 2010;55:S94-S97

AD Margolis, H Joseph, L Belcher, S Hirshfield, MA Chiasson. 'Never Testing for HIV' among Men who Have Sex with Men recruited from a sexual networking website, United States. AIDS and Behavior, 2012; 16: 23-9

OFFICE INFORMATION:

Public Health Solutions
220 Church Street, 5th floor
New York, NY 10013
Tel: 646-619-6411
Fax: 646-619-6777

NAME: Phyllis Della-Latta, PhD, MSc, D(ABMM) ACADEMIC TITLE: Director, Clinical Microbiology Service Professor of Clinical Pathology in Medicine

EDUCATION:
St. John’s University, MSc,
New York University, PhD, 1978

SPECIALTY:
Innovative laboratory diagnostic assays, molecular technology, rapid detection of hospital-associated and community-associated pathogens, multidrug resistant pathogens

RESEARCH SUMMARY:
Dr Phyllis Della-Latta is Professor of Clinical Pathology in Medicine and Director of the Clinical Microbiology Service at the Columbia University Medical Center, NYPH. She is the recipient of the Distinguished Achievements in Clinical Microbiology Award given by the American Society for Microbiology, NYC branch and is a fellow of the American Academy of Microbiology. Her current activities include USA editor-in-chief of the Reviews in Medical Microbiology, editor of Journal of Infections in Developing Countries and reviewer of several national and international scientific journals. Dr. Della-Latta has served as Chair of the Advisory Committee to the Commissioner of Health on emerging pathogens and bioterrorism and serves as advisor to many organizations, including the Food and Drug Administration medical devices committee. Her appointments in professional societies include President and both fund-raising and program chair of the American Society of Microbiology, NYC branch. She was a former chair of the Microbiology Section of the New York Academy of Sciences and served on the NYAS presidential advisory council.

SELECTED PUBLICATIONS:

Della-Latta P and Jonas V. Inhibitory effect of Alpha-Tec XPR-Plus phosphate buffer on the enhanced Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test.  J Clin Microbiol 37:1234-1235, 1999.

Della-Latta P. The Mycobacteriology Milestones: Journeying to the New Millennium.

Laboratory Medicine 30:408-417, 1999.

Catanzaro, A, Perry S, Clarridge JE, Dunbar S and Della-Latta P. The role of clinical suspicion in evaluating a new diagnostic test or active tuberculosis: results of a multi-center prospective trial. JAMA 283:639-645, 2000.

Wu F and Della-Latta P.  Molecular Typing Strategies. Review in Seminars in Perinatology 26 (5): pp. 357-366, 2002.

Jones RN, Della-Latta P, Lee L and Biedenbach DJ. Linezolid-Resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. Diagn Micro & Infect Dis 42:137-139, 2002.

Morel A-S, Wu F, Della-Latta P, Cronquist A, Rubenstein D and Saiman L. Nosocomial transmission of methicillin-resistant Staphylococcus aureus from a mother to her preterm quadruplet infants. Am J Infect Control 30:170-173, 2002.

Libre PE, Chin N-X and Della-Latta P. Intracameral antibiotics for endophthalmitis prophylaxis: A pharmacokinetic model.  J. Cataract & Refractive Surgery 29:1791-1794, 2003

Larson EL, Lin SX, Gomez-Pichardo C and Della-Latta P.  Effect of antibacterial home cleaning and handwashing products on infectious disease symptoms: a randomized, double-blind trial. Ann Intern Med 140:321-329, 2004.

Gupta A., Della-Latta P, Todd B, San Gabriel B,  Haas J, Wu F, Rubenstein D and Saiman L. Outbreak of extended-spectrum b-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails. Infect Control Hosp Epidemiol 25:210-215, 2004.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemotherapy 54:566-9, 2004.

Della-Latta P,  Mycobacteriology (Section Editor).  In Essential Procedures for Clinical Microbiology.  Chapter 7. 2nd ed. H.J. Isenberg (editor-in-chief). American Society for Microbiology, Washington DC, 2004.

Weiner RS, Della-Latta P and Schluger NW. Effect of nucleic acid amplification for Mycobacterium tuberculosis on clinical decision making in suspected extrapulmonary tuberculosis. Chest 128:102-107, 2005.

Pancholi P, Healy M, Bittner T, Webb R, Wu F, Aiello A, Larson E and Della-Latta P. Molecular characterization of hand flora and environmental isolates in a community setting. J. Clin. Microbiol 43:5202-5207, 2005.

Wu F and Della-Latta P. Pulsed- Field Gel Electrophoresis (PFGE). In Advanced Techniques in Diagnostic Microbiology, Part I, Chapter 9, pp. 143-157. Eds.Yi-Wei Tang and C.W. Stratton. Springer Science & Business Media, LLC, 2006.

Alberte-Castineiras, A, Brezmes-Valivieso MG, Campos-Bueno A, Montes-Martinez I, Lopez-Medrano R, Avellaneda C, Perez-Pascual P and Della-Latta P.  Drug-resistant tuberculosis in Castilla-Leon, Spain, 1996-2000. Int J Tuberc Lung Dis 10:554-558, 2006.

Graham PL, Della-Latta P, Wu F, Zhou J and Saiman L. The gastrointestinal tract serves as the reservoir for gram-negative pathogens in very low birth weight infants. Ped Infect Dis 26:1153-1155, 2007.

Chen KT, Campbell H, Borrell LN, Huard RC, Saiman L and Della-Latta P. Predictors and outcomes for pregnant women with vaginal-rectal carriage of community-associated methicillin-resistant Staphylococcus aureus. Am J. Perinatol 24:235-240, 2007.

Cook HA, Cimiotti JP, Della-Latta P, Saiman L and Larson EL.  Antimicrobial resistance patterns of colonizing flora on nurses’ hands in the neonatal intensive care unit. Amer J. Infect Control 35:231-236, 2007.

Della-Latta P. Nucleic Acid Amplification Tests (NAATs) for Direct Detection of M. tuberculosis Complex in Clinical Specimens; Approved Guideline, In Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS), Chapter 7.2, Volume 28, M48-A, Wayne, PA, 2008.

Schlaberg R, Huard RC and Della-Latta P. Nocardia cyriacigeorgica, an emerging pathogen in the United States. J. Clin. Micro 46:265-273, 2008.

Bodle ED, Cunningham JA, Della-Latta P, Schluger NW and Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emer Infect Dis 14:390-396, 2008.

Furuya EY, Paez A, Srinivasan A, Cooksey R,  Augenbraun M,  Baron M, Brudney K, Della-Latta P, Estivariz C,  Fischer S,  Flood M, Kellner P, Roman C, Yakrus M, Weiss D and Granowitz E. Outbreak of Mycobacterium abscessus wound infections among “lipotourists” from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 46:1181-1188, 2008.

Shepard JR, Addison RM, Alexander BD, Della-Latta P, Gherna M, Haase G, Hall G, Johnson JK, Merz WG, Peltroche-Llacsahuanga H, Stender H, Venezia RA, Wilson D, Procop GW, Wu F and Fiandaca MJ. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization methods for simultaneous dual-color identification of C.albicans and C.glabrata directly from blood culture bottles. J. Clin Micro 46:50-55, 2008.

Reich-Slotsky R., Wu F, Della-Latta P, Savage DG and Schwartz J. Application of pulsed-field electrophoresis to dienify the source of bacterial contamination of peripheral blood progenitor cell products. Transfusion 48:2409-2423, 2008.

Della-Latta P, Gjeltena L, Jost K., Metchock B, Roberts GD, Salfinger M, Schwabb D, Tans-Kersten J, Tran A, Warshauer D, Woods G and Wroblewski K. Mycobacterium tuberculosis: Assessing Your Laboratory. Association of Public Health Laboratories (APHL), 2009.

Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P and Huard RC. Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids fro Klebsiella strains isolated in a New York City Hospital. Antimicro Agents Chemother 53:1998-2004, 2009.

Reich-Slotky R, Kabbash DA, Della-Latta P, Blanchard JS, Feinmark SJ, Freeman S, Kaplan G, Shuman HA and Silverstein SC. Gemfibrozil (Lopid) inhibits Legionella pneumophila and Mycobacterium tuberculosis enoyl-coenzyme A reductases and blocks intracellular growth of these bacteria in macrophages. J Bacteriol 191:5262-5271, 2009.

Mittman SA, Huard RC, Della-Latta P and Whittier S. Comparison of BD Phoenix to Vitek 2, MicroScan MICroSTREP and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol 47:3557-3561, 2010.

Salgado C, Tenover FC, Arbeit RD, Carroll K, Della-Latta P, Francois P, Karchmer TB, Louie L, Nolte FS, Peterson LR, et al. Surveillance for methicillin-resistant Staphylococcus aureus: Principles, practices and challenges; A Report, In Clinical and Laboratory Standards Institute (CLSI), X07-R, Volume 30, No. 5, Wayne PA, 2010.

Carey AJ, Della-Latta P, Huard R, Wu F, Graham PL, Carp D and Saiman L. Changes in the molecular epidemiology of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Infect Control Hosp Epidemiol 31:613-619, 2010.

Morgan ME, Marlow E, Della-Latta P, Salimnia H, Novak-Weekley S, Wu F and Crystal BS. Multicenter evaluation of a new shortened peptide nuclei acid fluorescence in situ hybridization procedure for species identification of select gram-negative bacilli from blood cultures. J. Clin Microbiol 47:2269-2270, 2010.

OFFICE INFORMATION:
Department of Pathology
Clinical Microbiology Service, CHC 3-325
622 West 168th Street
New York, NY 10032
Tel: (212) 305-2929
Fax: (212) 305-8971
E-mail: pd23@columbia.edu

NAME: Jay Dobkin, MD ACADEMIC TITLE: Arnold P. Gold Foundation Associate Professor of Clinical Medicine

EDUCATION:
Columbia College, BA, 1968
Dartmouth Medical School, BMS, 1970
Harvard Medical School, MD, 1972

SPECIALTY: Antiretroviral therapy, harm reduction

RESEARCH SUMMARY:
Dr Jay Dobkin is the Arnold P. Gold Foundation Associate Professor of Clinical Medicine. Dr Dobkin is the director of the AIDS program at Columbia University Medical Center. He is the principal investigator of an ongoing series of quantitative assessments of interventions to promote improved adherence to antiretroviral therapy. Dr Dobkin is also developing assessment strategies for antiretroviral treatment programs targeting injection drug users in the former Soviet Union in collaboration with several nongovernmental organizations active in these areas including the Open Society Institute (New York) and the Open Health Institute (Moscow). He serves as a consultant to the World Health Organization on care and treatment of HIV-infected injection drug users. He is involved in research examining the pathogenesis of HIV-associated bone loss in a longitudinal cohort of postmenopausal women. Dr Dobkin is also the principal investigator of several industry-sponsored studies of new antiretroviral agents.

SELECTED PUBLICATIONS:
Cohn D, Dobkin JF. Treatment and prevention of tuberculosis in HIV infection. AIDS. 1993;7(suppl 1):S195-S202.

Brunswick A et al. HIV-1 seroprevalence and risk behaviors in an urban African American community cohort. Am J Public Health. 1993;83:1390-1394.

Gormam JM et al. Development and characteristics of a medical staging system for HIV infection. Int J Methods Psychiatr Res. 1993;2:117-124.

Thomas C, Dobkin JF, Weinberger O. TAT-medicated transcellular activation of HIV-1 long terminal repeat directed gene expression by HIV-1 infected peripheral blood mononuclear cells. J Immunology. 1994;153:3831-3839.

Lutfey M et al. Independent origin of mono-rifampin-resistant mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med. 1996;153:837-840.

Simpson D et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial. Neurology. 1996;44:1254-1259.

Bangsberg D et al. Reduction in tuberculin skin-test conversions among medical house staff associated with improved tuberculosis infection control practices. Infect Control Hosp Epidemiol. 1998;18:566-570.

Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV-infected postmenopausal women. Osteoporos Int. 2005;16:1345-1352.

Dobkin J. Preventing pneumococcal disease. AIDS Reader. 2006. 16(2):81-2
AIDS Read. 2006 Feb;16(2):81-2.

OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-8507
Fax: 212-305-7692
E-mail: Jfd2@columbia.edu

Back to Top

NAME: E. Yoko Furuya, MD, MS ACADEMIC TITLE: Assistant Professor of Clinical Medicine

EDUCATION:

Harvard University, BA, 1995
University of Pennsylvania School of Medicine, MD, 1999

Columbia University Mailman School of Public Health, MS (Epidemiology), 2006

SPECIALTY: Clinical research in hospital epidemiology and antimicrobial resistance

RESEARCH SUMMARY:
Dr. E. Yoko Furuya is the Medical Director of Infection Control and Hospital Epidemiology for NewYork-Presbyterian Hospital. She is also the Director of Antimicrobial Stewardship for NewYork-Presbyterian Hospital. Her research interests are focused in the areas of hospital epidemiology and antimicrobial resistance. She is a co-investigator on numerous NIH- and CDC-funded grants on topics such as multidrug-resistant gram-negative bacilli, the financial costs of healthcare-associated infections and antimicrobial resistance, and the impact of an automated infection control surveillance system on isolation precautions for/transmission of methicillin-resistant Staphylococcus aureus (MRSA). She is also currently working on the evaluation of antimicrobial stewardship interventions on antimicrobial utilization and resistance patterns, as well as the evaluation of a hand hygiene compliance program on the transmission of multidrug-resistant organisms.

SELECTED PUBLICATIONS:

Furuya EY, Lowy FD: Antimicrobial strategies for the prevention and treatment of cardiovascular infections including cardiothoracic surgery and device implants. Curr Opin Pharmacol 3: 464-9, 2003.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ: Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemotherapy 54: 566-9, 2004.

Furuya EY, Lowy FD: Antimicrobial-resistant bacteria in the community setting. Nature Rev Microbiol 4: 36-45, 2006.

Cook H, Furuya EY, Larson E, Vasquez G, Lowy FD: Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44: 410-3, 2007.

Furuya EY, Cook HA, Lee M, Miller M, Larson E, Hyman S, Della-Latta P, Mendonca E, Lowy FD: Community-associated methicillin-resistant Staphylococcus aureus prevalence: how common is it? A methodological comparison of prevalence ascertainment. Am J Infect Control 35: 359-66, 2007.

Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M, Baron M, Brudney K, Della-Latta P, Estivariz C, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV: Outbreak of Mycobacterium abscessus wound infections in US lipotourists who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 46: 1181-8, 2008.

Stone PW, Dick A, Pogorzelska M, Horan TC, Furuya EY, Larson E: Staffing and structure of infection prevention and control programs. Am J Infect Control 37: 351-7, 2009.

Miller M, Cook HA, Furuya EY, Bhat M, Lee MH, Vavagiakis P, Visintainer P, Vasquez G, Larson E, Lowy FD: Staphylococcus aureus in the community: colonization versus infection. PLoS One: 4: e6708, 2009.

Furuya EY, Kubin CJ: Antibiotic prophylaxis. In: Cohen, Powderly, and Opal, eds. Infectious Diseases, 3rd ed. Oxford: Mosby Elsevier; 2010. pp. 1323-1332. 

Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ: Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 67: 180-4, 2010.

Furuya EY, Dick A, Perencevich EN, Pogorzelska M, Goldmann D, Stone PW: Central line bundle implementation in US intensive care units and impact on bloodstream infections. PLoS One 6:e15452, 2011.

Furuya EY, Larson E, Landers T, Jia H, Ross B, Behta M: Challenges of applying the SHEA/HICPAC metrics for multidrug-resistant organisms to a real-world setting. Infect Control Hosp Epidemiol 32: 323-32, 2011.

Pogorzelska M, Stone PW, Furuya EY, Perencevich EN, Goldmann D, Dick A: Impact of the ventilator bundle on ventilator associated pneumonia in intensive care units. Int J Qual Health Care 23: 538-44, 2011.

Apte M, Neidell M, Furuya EY, Caplan D, Glied S, Larson E: Using electronically available inpatient hospital data for research. Clin Trans Sci 4: 338-45, 2011.

Bright TJ, Furuya EY, Kuperman GJ, Cimino JJ, Bakken S: Development and evaluation of an ontology for guiding appropriate antibiotic prescribing. J Biomed Inform 45: 120-8, 2012.

Kubin CJ, Jia H, Alba LR, Furuya EY: Lack of significant variability among different methods for calculating antimicrobial days of therapy. Infect Control Hosp Epidemiol 33 (Special Topic Issue: Antimicrobial Stewardship): 421-3, 2012. 

Furuya EY, Dick A, Perencevich EN, Pogorzelska M, Goldmann D, Stone PW: Central Line Bundle Implementation and Impact on Infection Rates in US Intensive Care Units (ICU). Oral Presentation, “The Cutting Edge of Infection Prevention: The Top Four Submitted Papers of the 2010 Decennial.” Abstract #2289. Fifth Decennial International Conference on Healthcare-Associated Infections, March 2010. Atlanta, GA.

 

OFFICE INFORMATION:

Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: eyf2002@columbia.edu

NAME: Peter Gordon, MD

ACADEMIC TITLE:
Assistant Professor of Clinical Medicine

EDUCATION:
SUNY at Stony Brook, BS, 1986
SUNY at Stony Brook, School of Medicine, MD, 1990

SPECIALTY: HIV primary care, HIV clinical trials, HIV/HCV coinfection

RESEARCH SUMMARY:
Dr Gordon is an assistant professor of clinical medicine in the Division of Infectious Diseases at CUMC and the medical director of the NewYork–Presbyterian System Select Health, an HIV Special Needs Plan (SNP). He is also a coinvestigator for the Adult AIDS Clinical Trials Unit at CUMC and a principal investigator for industry-sponsored studies of new antiretroviral agents.

OFFICE INFORMATION:
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-9396
Fax: 212-305-7692
E-mail: pgg2@columbia.edu

NAME: Rachel J. Gordon, MD, MPH ACADEMIC TITLE: Assistant Professor of Clinical Medicine Assistant Professor of Clinical Epidemiology

EDUCATION:
Yale University, B.S., 1996
Vanderbilt University School of Medicine, M.D., 2000
Columbia University Mailman School of Public Health, M.P.H. 2004

SPECIALTY: Staphylococcal molecular epidemiology and pathogenesis

RESEARCH SUMMARY:
Dr Rachel Gordon is an Assistant Professor in clinical medicine in the Division of Infectious Diseases at the Columbia University Medical Center.
Her research interests include the molecular epidemiology of Staphylococcal colonization and disease as well as Staphylococcal pathogenesis.
In a past project, she described two major Staphylococcus aureus clonal types colonizing and infecting AIDS patients in a drug rehabilitation facility.
This research demonstrated instability of the mec element, which is responsible for methicillin-resistance. Currently, she is completing a double-blinded, randomized controlled trial of mupirocin vs. placebo in the same population to see if nasal carriage and infection with S. aureus can be reduced. Currently, Dr. Gordon is investigating the molecular epidemiology and pathogenesis of S. epidermidis in ventricular assist device-related infections. She is also interested in bacterial infections in drug users.

SELECTED PUBLICATIONS:
Cespedes, C., B. Said-Salim, M. Miller, S.H. Lo, B.N. Kreiswirth, R.J. Gordon , P. Vavagiakis, R.S. Klein, and F.D. Lowy FD. The clonality of Staphylococcus aureus nasal carriage.  J. Infect. Dis. 2005;191(3):444-52. 

Gordon, R.J., B. Quagliarello, C. Cespedes, M. Chung, H. de Lencastre, P. Vavagiakis, M. Miller, B. Zeller, and F.D. Lowy.  A Molecular Epidemiological Analysis of 2 Staphylococcus aureus Clonal Types Colonizing and Infecting Patients with AIDS.  Clin. Infect. Dis. 2005;40:1028-1036.

Gordon, R.J. and F.D. Lowy.  Bacterial Infections in Drug Users.  NEJM 2005; 353:1945-54.

Gordon, R.J., B. Quagliarello, and F.D. Lowy.  Ventricular assist device-related infections. Lancet Infect. Dis. 2006; 6:426-37.

Gordon, R.J. and F.D. Lowy.  Pathogenesis of Methicillin-Resistant Staphylococcus aureus Infection.  Clinical Infectious Diseases 2008; 46:S350-9.

Schulman AR, Martens TP, Russo MJ, Christos PJ, Gordon RJ, Lowy FD, Oz MC, Naka Y. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant. 2009 Mar;28(3):237-42.

ABSTRACTS

Jankolovits, R., B. Quagliarello, C. Cespedes, M. Miller, M. Chung, H. De Lencastre, B. Zeller, J. Justman,  and F.D. Lowy. Two clonal types of Staphylococcus aureus dominate infection and nasal colonization in a NYC AIDS and drug treatment facility. Slide presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September, 2002.

Gordon, R. J., T. Martens, R. Wang, Y. Naka, B. Scully, E. Blumberg, and F. Lowy. Diagnostic Criteria for Diagnosing Ventricular Assist Device-Related Infections. Poster presentation at the 46th ICAAC, September, 2006.

R. Gordon, M. Bhat, C. Fairchild, J. Choe, U. Rawiel, D. Ascheim, M. Slaughter, Y. Naka, F. Lowy. Ventricular Assist Device Recipients Share Commensal S. epidermidis Clones and are Infected with Colonizing Strains. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.

R. Gordon, N. Chez, H. Jia, B. Zeller, M. Sobieszczyk, C. Brennan, K. Hisert, M. Lee, P. Vavagiakis, F. Lowy. Monthly mupirocin decreases S. aureus nasal colonization in HIV/AIDS patients. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.

Uhlemann-AC, Huard-R, Whittier-S, Della-Latta-P, Lowy-FD, Gordon-RJ. Clinical Vancomycin-Intermediate S. aureus (VISA) infection with a USA 300 strain. 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC., October 2008.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Phone: (212) 342-0109
Fax (212) 305-5794

E-mail: rj216@columbia.edu

NAME: Sandra Hyman, RN, MPA, CIC ACADEMIC TITLE: Associate in Medicine

EDUCATION:

Molloy College, BS, 1981 

New York University, MPA, 1986

SPECIALTY: Infection Prevention and Control

RESEARCH SUMMARY:

Sandra R. Hyman, RN, MPA, CIC , has been an  Infection Prevention Specialist  at NewYork-Presbyterian Hospital (NYPH) for over 8 years, and is an Associate in Medicine at the Columbia University, Department of Medicine, Division of Infectious Diseases. For the last 4 years at (NYPH) she has been providing education and infection prevention support for the adult and children’s Perioperative Services. She is part of the Perioperative Services Leadership.   In addition, Sandra Hyman has been a member of a research team at the Columbia University Center for Interdisciplinary Research to Reduce Antimicrobial Resistance.  The team had a NIH Grant to study the economics of hospital infections.

Prior to NYPH she was an Infection Control Coordinator at Greenwich Hospital, in Greenwich, Connecticut (CT) for 15 years.  She specialized in community acute care, home care and private office consulting. Sandra also managed some Employee Health functions. Sandra has been a member of The Association for Professionals in Infection Control and Epidemiology  (APIC) for over 25 years, and served as Vice Chairman for the CT APIC Conference.  She is currently a member of the APIC National Education Committee and the Education Committee liaison for the APIC Professional Development Committee.   

Sandra is on the Advisory Board for the American Journal of Infection Control (AJIC) and has reviewed articles AJIC and the Joint Commission Journal on Quality and Patient Safety.

SELECTED PUBLICATIONS:
Frequency, Level, and Duration of Patient Contacts, And Observational Study and Survey of Physicians, Nurses, Clinical Staff and Visitors, The Joint Commission Journal of Quality and Patient Safety

S. Hyman, RN, MPA, CIC, L. Kertesz, ANP, MSN, CNOR, P. Nelson, RN, MSN,P. Nelson, RN, MSN, CNOR, A. Compton, MD, MPH, V. Almarez-Fox, RN, MPA, J. Evanko, MD, MBA, Engaging Staff to be Responsible for Surgical Site Infection Prevention in a Large Academic Tiertiary Hospital, Association for Professionals in Infection Control and Epidemiology, San Antonio, Texas.

Cohen B, Choi YJ, Hyman, SR, Furuya, EY, Neidell M, Larson, EL, Gender Differences in Risk of Bloodstream Infection, Association for Professionals in Infection Control and Epidemiology, San Antonio, Texas

S. Hyman, RN, MPA, CIC, K. Gasiorowski, RN, MSN, CNOR, L.Kertesz, ANP, MSN, CNOR, L. Posner, RN, BSN, M. O’Brien, RN, MA, CNOR SCIP-ing to the Next Level: Surgical Site Infection Prevention, Association of periOperative Registered Nurses, New Orleans, Louisiana.

M. Apte,MS, T. Landers, RN, Ph.D, E. Furuya, MD, MS, S. Hyman, RN, MPA,E. Larson, RN, PhD, A Comparison of Two Computer Algorithms to Identify Surgical Site Infections, Journal of Surgical Infections 2011 Dec;12(6):459-64.

  

S. Hyman, RN, MPA, CIC, B. Cohen, MPH, L. Rosenberg, BS, E. Larson, RN, Ph.D, Frequency, Level, and Duration of Patient Contacts, And Observational Study and Survey of Physicians, Nurses, Clinical Staff and Visitors, Association for Infection Prevention, Baltimore, Maryland, New York Academy of Medicine, Nursing Research Seminar

T. Landers, CNP, Ph.D, M. Apte, MBBS, MsPH, S.Hyman, RN,MPA,CIC,  E. Y. Furuya, MD, S. Glied, PhD, E. Larson, RN, PhD, A Comparison of Methods to Detect Urinary Tract Infections Using Electronic Data, The Joint Commission Journal of Quality and Patient Safety.

S. Hyman, RN, MPA, CIC, P. Bernstein, BSN, RN, CIC, S. Shim, RN, BSN, CNOR., M. Messina, RN, BSN, P. Angevine, MD, MPH, et.al. A Multidisciplinary Approach to Surgical Site Infection Reduction, Association for Infection Prevention, New Orleans, Louisiana

M. Apte, MBBS,MsPH, T. Landers, CNP, PhD, E. Y. Furuya, MD, MS, S. Hyman,RN, MPA, CIC, E. Larson, RN, PhD, A Comparison of Performance of Two Computer Algorithms to Identify Surgical Site Infections Using Electronic Data, Association for Infection Prevention, New Orleans, Louisiana

B. Ross, RN, BSN, CIC, R. Chaudry, MS, S. Hyman, RN, MPA,CIC, F. Hong, MA, M. Fracaro, RN, MA, CIC, B. Forman, MD, M. Behta,PharmD,A Solution for New York State’s Public Reporting Requirement:  An Automated Surveillance System for Central Line-Associated Bloodstream Infections (CLABSI), Annual NPSF Safety Congress, Nashville, Tennessee

  

E. Y. Furuya, MD, H. Cook, MPH, H. Lee, BS, M. Miller, Ph.D, E. Larson, PhD, S. Hyman, RN, MPA, CIC, P. Della-Latta, PhD, E. Mendonca, MD, Ph. D., and F. Lowy, MD, Community-associated methicillin resistant Staphylococcus aureus prevalence: How common is it.  A methodological comparison of prevalence ascertainment.  American Journal of Infection Control, Volume 35 No. 6, 359-366.

S. Hyman, RN,MPA,CIC, P. Bernstein, RN, BSN, CIC, N. Schneider, RN, MS, CIC, S. O’Sullivan, RN, BSN, CIC, A. Castellanos, MBA, “Operation Come Clean- A Novel Approach to Improving Hand Hygiene

Compliance”, American Journal of Infection Control, Volume 35, Issue 5, Pages E107 –E108.

E. Chen, Ph.D, D. Wajngurt, MD, MA, K. Qureshi, S. Hyman, RN, MPA, G. Hripcsak, MDS, MS, Automated Real-time Detection and Notification of Positive Infection Cases, American Medical Informatic Association Symposium.

D. Wajngurt MD, MA, .F. Hong, MA, R. Chaudry, MS, E. Hwang, MD, S. Hyman, RN, B. Ross, RN, M. Fracaro, RN , EpiPortal: An Electronic Decision Support System for Infection Control, American Medical Informatic Association Symposium.

JP Haas, RN, MS, D. Quiros, MS, SR, Hyman, MPA, EL Larson, RN, Ph.D, Use of an Innovative Game to Teach and Reinforce Hand Hygiene Compliance among Healthcare Workers, Association for Practitioners in Infection Control Conference and International Meeting.

  

Carey AJ, Graham PL, Hyman S, Carp D, Wu F, Della-Latta P, Rubenstein D, Saiman L. Molecular epidemiology of methicillin resistant Staphylococcus aureus in a level III-IV neonatal intensive care unit. Society of Pediatric Research, San Francisco, CA

EY Furuya, H. Cook, S. Hyman, et. al., Prevalence of Community-Associated Methicillin-Resistant Staphylococcus aureus: Methodology-Based Disparities.  Interscience Antimicrobial Agents and Chemotherapy Conference

Hyman S, Wajngurt D, Hwang E, Furuya EY, Hong F, Fracaro M, Hammer S, Shortliffe E et al. Model for Designing Advanced Technological Tools to Enhance Infection Control Surveillance.  Society for Healthcare Epidemiologists of America.

Hyman et al. Streamlining Daily Infection Control Surveillance: Implementation Of A Novel Information System At The Columbia University  Medical Center. Society for Healthcare Epidemiology of America.

Marino, P, RN, Franco, M., MD, Hyman, S, RN “Community Acquired Pneumonia., Qualidigm Poster Presentation, Waterbury, CT

Sabetta, JR, MD, Hyman, SR, MPA,CIC, Smardin, J., CIC, “Foodborne Nosocomial Outbreak of Salmonella reading - Connecticut”MMWR, and JAMA, December 25,1991.

 

OFFICE INFORMATION:

177 Fort Washington Avenue

Milstein 3GN Room 432

New York, NY 10032

Tel: 212-305-4611

Fax: 212-305-8292

NAME: Jessica Justman, MD ACADEMIC TITLE: Associate Professor of Clinical Medicine (in Epidemiology)

EDUCATION:
Yale University, BS, 1981
University of Rochester, MD, 1985

SPECIALTY: HIV epidemiology, HIV prevention clinical research,  metabolic complications of antiretroviral therapy

RESEARCH SUMMARY:
Dr. Justman’s primary research interest is in HIV prevention. She has conducted several HIV prevention clinical trials and, as principal investigator of the Bronx-Lebanon Hospital Center’s Microbicide Trials and HIV Prevention Trials Networks (MTN/HPTN) site, continues to conduct Phase I and II safety studies of vaginal microbicides at Bronx-Lebanon.  She also serves as Co-Chair of the HPTN’s Women’s HIV Seroincidence Study (ISIS). She has been an active investigator with the NIAID-funded Women’s Interagency HIV Study, a large epidemiologic study of HIV in women in the US. Dr. Justman was instrumental in identifying risks associated with diabetes and other metabolic complications in these women and the metabolic side-effects of HIV and antiretroviral therapy has remained an important  research interest.

At the Mailman School of Public Health, Dr. Justman serves as Associate Director of the Center for Infectious Diseases Epidemiologic Research (CIDER) within the Department of Epidemiology, and  Senior Technical Director of the International Center for AIDS Care and Treatment Programs (ICAP).   Dr. Justman oversees ICAP’s clinical, monitoring and evaluation, and health systems strengthening activities.

SELECTED PUBLICATIONS:
J.E. Justman, L. Benning, A. Danoff, H. Minkoff, A. Levine, R.M. Greenblatt, K. Weber, E. Piessens, E. Robinson, K. Anastos. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302.

Zevallos M, Justman JE. Tuberculosis in the elderly. Clin Geriatr Med. 2003 Feb;19(1):121-38. Review.

Tien PC, Cole SR, Williams CM, Li R, Justman JE, Cohen MH, Young M, Rubin N, Augenbraun M, Grunfeld C. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):461-6.

Tien PC, Kovacs A, Bacchetti P, French AL, Augenbraun M, Cole SR, Hessol N, Justman J; Women's Interagency HIV Study. Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. Clin Infect Dis. 2004 Nov 1;39(9):1363-70. Epub 2004 Oct 7.

K.H. Mayer, L.A.Maslankowski, F. Gai, W.M. El-Sadr, J. Justman, A. Kwiecien, B. Masse, S.H. Eshleman, C. Hendrix, K. Morrow, J.F. Rooney, L. Soto-Torres.  Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006. 20(4):543-51.

J.E. Justman, D.R. Hoover, Q. Shi , T. Tan, K. Anastos, P.C. Tien ,S.R. Cole, C. Hyman , R. Karim, K. Weber, S. Grinspoon.  Longitudinal anthropometric patterns among HIV-infected and –uninfected women. JAIDS 2008 47: 312-9.

M.E. Sobieszczyk, D.R. Hoover, K. Anastos, K. Mulligan, T. Tan, Q. Shi, W. Gao, C. Hyman, M.H. Cohen, SR. Cole, M.W. Plankey, A.M. Levine, J. Justman. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study.  J Acquir Immune Defic Syndr  2008 48:272-80.

M. Gasana, G. Vandebriel, G. Kabanda, S.J. Tsioursis, J. Justman, R. Sahabo, D. Kamugundu, W.M. El-Sadr. Integrating tuberculosis and HIV care in rural Rwanda. Int J Tuberc Lung Dis. 2008 12 (3 S1): 39-43.

B. Cutler, J. Justman. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008 11:685-97.J.E. Justman, S. Koblavi-Deme, A. Tanuri, A. Goldberg, L.F. Gonzalez, C.R.Gwynn. Developing laboratory systems and infrastructure for HIV scale-up: A tool for health systems strengthening in resource-limited settings. J Acquir Immune Defic Syndr. 2009 Nov;52 Suppl 1:S30-3.

Wang Z, Chin SY, Chin CD, Sarik J, Harper M, Justman J, Sia SK. Microfluidic CD4+ T-cell counting device using chemiluminescence-based detection. Anal Chem. 2010 Jan 1;82(1):36-40.

Peter T, Blair D, Reid M, Justman J. DART and laboratory monitoring of HIV treatment. Lancet. 2010 Mar 20;375(9719):979.

Vermund SH, Hodder SL, Justman JE, Koblin BA, Mastro TD, Mayer KH, Wheeler DP, El-Sadr WM. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis. 2010 May 15;50 Suppl 3:S149-55. Review.

Nuwagaba-Biribonwoha H, Werq-Semo B, Abdallah A, Cunningham A, Gamaliel JG, Mtunga S, Nankabirwa V, Malisa I, Gonzalez LF, Massambu C, Nash D, Justman J, Abrams EJ. Introducing a multi-site program for early diagnosis of HIV infection among HIV-exposed infants in Tanzania. BMC Pediatr. 2010 Jun 17;10:44.

Justman J, El-Sadr WM. AIDS response at a crossroads. Science. 2010 Jul 9;329(5988):120.

Hodder SL, Justman J, Haley DF, Adimora AA, Fogel CI, Golin CE, O'Leary A,Soto-Torres L, Wingood G, El-Sadr WM; HIV Prevention Trials Network Domestic Prevention in Women Working Group. Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S69-73.

Chin CD, Laksanasopin T, Cheung YK, Steinmiller D, Linder V, Parsa H, Wang J, Moore H, Rouse R, Umviligihozo G, Karita E, Mwambarangwe L, Braunstein SL, van de Wijgert J, Sahabo R, Justman JE, El-Sadr W, Sia SK. Microfluidics-base diagnostics of infectious diseases in the developing world. Nat Med. 2011 Jul 31;17(8):1015-9. doi: 10.1038/nm.2408.

Justman J, El-Sadr WM. Stemming the U.S. HIV epidemic: act local. Science. 2012 Jul 27;337(6093):411.

OFFICE INFORMATION:
722 W 168th Street, Room 713
Columbia University Medical Center
New York, New York 10032
Tel: 212-342-0537
E-mail: jj2158@columbia.edu

NAME: Charles Knirsch, MD, MPH ACADEMIC TITLE: Adjunct Assistant Professor of Medicine

EDUCATION:
McGill University, BSc, 1981
McGill University, MD, 1985
Columbia University, MPH, 1995

SPECIALTY: TB, travel medicine

RESEARCH SUMMARY:

Charles Knirsch, MD, MPH research has integrated work with several Public-Private-Partnerships to collaborate on disease control and elimination programs. This has involved work on addressing information management for tuberculosis patient treatment protocols and hospital epidemiology in New York to more recent international sector collaborations on malaria with The National Institutes of Health and The Centers for Disease Control and Prevention. Chuck currently collaborates with The World Health Organization and The International Trachoma Initiative on a program to eliminate blinding trachoma by the year 2020.

SELECTED PUBLICATIONS:

Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Noncompliance with antituberculosis treatment: Predictors and consequences in New York City. Am J Med 1997;102:164-170.

Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574-579.

Knirsch CA, Jain NL, Pablos-Mendez A, Friedman C, Hripcsak G.  Tuberculosis Detection and Moni­toring by an Automated Clinical Decision Support System. Infect Control Hosp Epidemiol 1998;19 (2) 94-100.

Hripcsak G, Knirsch CA, Jain N, Stazesky RC, Pablos-Mendez A, Fulmer T. A health information network for managing inner-city Tuberculosis: Bridging clinical care, public health, and home care. Computers and Biomedical Research 1999 Feb;32 (1):67-76.

Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Méndez A. Neighborhood poverty and the resurgence of Tuberculosis in New York City, 1984 to 1992. Am J Public Health 2001 Sep;91(9):1487-93.

Mecaskey JW, Knirsch CA, Kumaresan JA, Cook JA. The possibility of eliminating blinding trachoma. Lancet Infect Dis. 2003 Nov;3(11):728-34.

Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya H, Ohrt C, Knirsch C. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis. 2006 Nov 15;43(10):1264-71.

Noedl H, Krudsood S, Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother. 2007 Feb;51(2):651-6.

Knirsch C. Trachoma: ancient scourge, disease elimination, and future research.
Curr Infect Dis Rep. 2007 Jan;9(1):21-8.

El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. The Effect of Azithromycin on Ivermectin Pharmacokinetics – A Population Pharmacokinetic Model Analysis. PLoS Negl Trop Dis. 2008 May 14;2(5):e236.

OFFICE INFORMATION:
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

NAME: Christine J. Kubin, PharmD, BCPS ACADEMIC TITLE: Assistant in Medicine

EDUCATION:
University of North Carolina at Chapel Hill, PharmD, 1998

SPECIALTY: Anti-infective pharmacology and therapeutics, antimicrobial resistance and epidemiology, antifungal therapy

RESEARCH SUMMARY:
Dr Kubin is the clinical pharmacy manager in the Division of Infectious Diseases at NewYork–Presbyterian Hospital, Columbia University Medical Center and a board-certified pharmacotherapy specialist. Her research interests focus on anti-infective treatment outcomes and the epidemiology of multi-drug resistant pathogens. Dr Kubin is a member of the joint Anti-Infective Subcommittee at NewYork–Presbyterian Hospital and co-spearheads antimicrobial stewardship activities with Dr. Furuya. Current projects include evaluating treatment outcomes and therapies for infections caused by carbapenem-resistant organisms, evaluating the relationships of antibiotic utilization and resistance within the hospital, and creating microbiology and antibiotic utilization components of the computer-assisted hospital infection control surveillance system currently in development.

SELECTED PUBLICATIONS AND ABSTRACTS:

Zeana C, Kubin CJ, Della-Latta P, Hammer S. Vancomycin-resistant /Enterococcus faecium/ meningitis successfully managed with linezolid: Case report and review of the literature. /Clin Infect Dis./ 2001 Aug  > 15;33(4):477-482.

Kubin CJ. Antimicrobial control programs. /Semin Perinatol./ 2002 Oct;26(5):379-386.

Furuya EY, Sobieszczyk ME, Kubin CJ, Hay CM. Intraventricular polymyxin B for the treatment of multi-drug resistant gram-negative bacillary  > ventriculitis: Two successful cases. Abstract presented at: 41st Annual Meeting of the Infectious Diseases Society of America; October 9-12, 2003; San Diego, CA.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM,  > Kubin CJ. Combination therapy with polymyxin B for the treatment of multi-drug resistant gram-negative respiratory tract infections. /J Antimicrob Chemoth./ 2004 Aug;54(2):566-569.

Hammer S, Kubin CJ. Antiretroviral Agents. In: Cohen J, Powderly WG, eds. /Infectious Diseases, 2nd ed./ Spain: Elsevier Limited; 2004:1871-1893.

Kubin CJ, Lam S, Hammer SM, Della-Latta P, Yin MT. Impact of caspofungin compared to fluconazole and lipid amphotericin B on outcomes in patients with candidemia. Abstract presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.

Kubin CJ, Dzierba A. The effects of continuous renal replacement therapy (CRRT) on anti-infective therapy in the critically ill. /J Oncol Pharm  > Pract./ 2005;18:109-117.

Wong KK, Kubin CJ, Furuya EY.  Characterization of carbapenem-resistant Klebsiella pneumoniae and comparison with carbapenem-susceptible Klebsiella pneumoniae in bacteremias.  Abstract presented at: Annual Meeting of the Infectious Diseases Society of America; October 4-7, 2007; San Diego, CA.

Patel SJ, Larson EL, Kubin CJ, Saiman L.  A Review of Antimicrobial Control Strategies in Hospitalized and Ambulatory Pediatric Populations. Pediatr Infect Dis J  2007; 26(6):531-537.

Kubin CJ.  Antimicrobial stewardship programs: role in optimizing infectious disease outcomes.  Disease Management and Health Outcomes 2008; 16(6): 403-410.

Kessler J, Della-Latta P, Whittier S, Sobieszczyk ME, Kubin CJ.  Changes in susceptibility to polymyxin B amongst clinical specimens in a New York hospital, 2005-2008.  Abstract presented at: Annual Meeting of the Infectious Diseases Society of America 2009; Philadelphia, PA.

Mehta M, Kessler J, Murphy K, Chan G, Della-Latta P, Whittier S, Sobieszczyk ME, Kubin CJ.  Evaluation of patients with polymyxin and/or tigecycline resistant gram-negative isolates.  Abstract presented at 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2009; San Francisco, CA.

Kessler J, Kubin CJ, Mehta M, Murphy K, Chan G, Della-Latta P, Whittier S, Sobieszczyk ME. Epidemiology and outcomes of polymyxin or tigecycline resistant gram-negative bacteremias in a New York hospital.  Abstract presented at 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2009; San Francisco, CA.

Ma K, Dzierba AL, Kubin CJ.  Effect of Vancomycin Trough levels and minimum inhibitory concentrations on outcomes in methicillin-resistant Staphylococcus aureus pneumonia.  Abstract presented at 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2009; San Francisco, CA.

Kludze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Medical Mycology 2010; 48(2):436-9.

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: cck27@columbia.edu

NAME: Franklin Lowy, MD ACADEMIC TITLE: Professor of Medicine and Pathology

EDUCATION:
Columbia College BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972

SPECIALTY: Internal Medicine and Infectious Diseases

RESEARCH SUMMARY:

Dr Franklin Lowy is professor of medicine and pathology in the Division of Infectious Diseases in the College of Physicians and Surgeons at Columbia University. His laboratory investigates the pathogenesis and epidemiology of Staphylococcus aureus and Staphylococcus epidermidis infections.

Studies on the pathogenesis of staphylococcal infections: Recent projects have focused on the role of different S. aureus and S. epidermidis surface proteins as mediators of adherence to explanted left ventricular assist device (LVAD) material. The goal of these studies has been to characterize the role of these proteins in the initiation of device-related infections. A second series of studies have used a mouse post-influenza model for S. aureus pneumonia to investigate the pathogenesis of these life-threatening infections.

Studies on the transmission of S. aureus among high-risk populations: A household-based study is underway to investigate how CA-MRSA is spread in the predominantly Dominican population that surrounds Columbia University Medical Center. Genetic characterization of these isolates as they spread within the community will examine whether adaptive changes facilitate spread. The goal of these studies is to gain a better understanding of the factors that contribute to the dissemination of S. aureus within this population. A second component of this investigation is to examine the spread of a unique methicillin-susceptible S. aureus, strain ST398. This strain is prevalent in Northern Manhattan and is responsible for an increasing number of clinical infections. A second transmission study is underway to determine how CA-MRSA strains are introduced and spread into the NYS prison system. The study, performed at Sing Sing and Bedford Hills maximum-security prisons examines inmates at entry, during their stay and at release from the two prisons. Molecular epidemiologic techniques are used to characterize the predominant isolates in the two facilities.

SELECTED PUBLICATIONS:

Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.

Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest. 2003;111:1265-1273.

Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med. 2005;353:1945-1954.

Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nature Microbiol Rev. 2006;4:36-45.

Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect Dis. 2006;6:426-37.

Lowy, F.D., Aiello, A.E., Bhat, M., Johnson-Lawrence, V.D., Lee, M., Burrell, E., Wright, L.N., Vasquez, G. and Larson, E.L. Staphylococcus aureus colonization and infection in New York State Prisons. J. Infect. Dis. 196:911-918, 2007

Arrecubieta, C., Lee, M., Macey, A., Foster, T.J. and Lowy, F.D. SdrF, a Staphylococcus epidermidis surface protein, binds type 1 collagen. J. Biol. Chem. 282:18767-18776, 2007

Lowy, F. D. Secrets of a superbug. Nat. Med.13:1418-1420, 2007

Arrecubieta, C., Francis, F.A.T.,von Bayern, M. P., Akashi, H., Deng, M.C., Naka, Y. and Lowy, F.D. SdrF, a Staphylococcus epidermidis surface protein, contributes to the initiation of ventricular assist device driveline-related infections. PLoS Pathogens 5:e1000411-1000424, 2009

Lee M.H., Arrecubieta C., Martin F.J., Prince A., Borczuk A.C. and Lowy F.D. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis 201:508-15, 2010

Gwizdala, R., Miller, M., Bhat, M., Vavagiakis, P., Henry, C., Neaigus, A., Shi, Q. and Lowy, F.D. Staphylococcus aureus among drug users: identification of hidden networks. Amer. J. Pub. Health. In Press 2011

Lowy, F.D. Staphylococcal Infections In: Harrison’s Principles of Internal Medicine, 18th edition. Editors: A. S. Fauci, E. Braunwald, D.L. Casper, S. L. Hauser, D. L. Longo, J. L. Jameson and J. Loscalzo. The McGraw-Hill Companies, Inc., In Press 2011

LABORATORY HOMEPAGE:

http://www.columbia.edu/cu/lowylab/

OFFICE INFORMATION:
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, 9-458
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-5794
E-mail: fl189@columbia.edu